ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025
Erratum: A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in a Treatment-Naive CLL Population Enriched for High-Risk Disease.
No numbers read from the abstract.